GlassScriptPhysician profile
Mary Cvitkovic
NPI 1669134136
$502.93
in general payments reported to CMS, 2019-2025
14 companies · $234 in 2025
The $234 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $120 · 2023: $102 · 2024: $47.08 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $383.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $109.56 | 2025 | Orserdu |
| Genentech USA, INC. | $63.02 | 2025 | Itovebi |
| Seagen INC. | $59.30 | 2022-2023 | Tukysa |
| Gilead Sciences, INC. | $38.26 | 2022-2023 | Trodelvy |
| Lilly USA, LLC | $35.33 | 2022-2023 | Retevmo, Jaypirca, Verzenio |
| Merck Sharp & Dohme LLC | $34.12 | 2023-2025 | Lynparza, Keytruda, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $30.95 | 2024 | |
| Genmab U.S., INC. | $24.92 | 2025 | |
| Daiichi Sankyo INC. | $23.82 | 2022 | |
| Janssen Biotech, INC. | $20.13 | 2025 | Rybrevant |
| Astrazeneca Pharmaceuticals LP | $18.18 | 2022 | |
| Pfizer INC. | $16.13 | 2024 | |
| Adc Therapeutics America, INC. | $14.99 | 2023 | |
| Incyte Corporation | $14.22 | 2023 | Pemazyre, Jakafi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Cvitkovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.